D
AC Immune SA
ACIU
$1.88
$0.0854.74%
D
Sell
8/8/2024Upgraded
AC Immune SA (ACIU) was upgraded to D- from E+ on 8/8/2024 due to an increase in the volatility index and total return index.
AC Immune SA (ACIU) was upgraded to D- from E+ on 8/8/2024 due to an increase in the volatility index and total return index.
E
Sell
7/24/2024Downgrade
AC Immune SA (ACIU) was downgraded to E+ from D- on 7/24/2024 due to a decline in the volatility index.
AC Immune SA (ACIU) was downgraded to E+ from D- on 7/24/2024 due to a decline in the volatility index.
D
Sell
7/5/2024Upgraded
AC Immune SA (ACIU) was upgraded to D- from E+ on 7/5/2024 due to an increase in the volatility index, total return index and valuation index.
AC Immune SA (ACIU) was upgraded to D- from E+ on 7/5/2024 due to an increase in the volatility index, total return index and valuation index.
E
Sell
6/17/2024Downgrade
AC Immune SA (ACIU) was downgraded to E+ from D- on 6/17/2024 due to a decline in the volatility index and valuation index.
AC Immune SA (ACIU) was downgraded to E+ from D- on 6/17/2024 due to a decline in the volatility index and valuation index.
D
Sell
5/29/2024Upgraded
AC Immune SA (ACIU) was upgraded to D- from E+ on 5/29/2024 due to an increase in the volatility index and total return index.
AC Immune SA (ACIU) was upgraded to D- from E+ on 5/29/2024 due to an increase in the volatility index and total return index.
E
Sell
5/17/2024Downgrade
AC Immune SA (ACIU) was downgraded to E+ from D- on 5/17/2024 due to a decline in the volatility index and valuation index.
AC Immune SA (ACIU) was downgraded to E+ from D- on 5/17/2024 due to a decline in the volatility index and valuation index.
D
Sell
5/2/2024Upgraded
AC Immune SA (ACIU) was upgraded to D- from E+ on 5/2/2024 due to an increase in the volatility index, total return index and valuation index.
AC Immune SA (ACIU) was upgraded to D- from E+ on 5/2/2024 due to an increase in the volatility index, total return index and valuation index.
E
Sell
4/12/2024Downgrade
AC Immune SA (ACIU) was downgraded to E+ from D- on 4/12/2024 due to a decline in the volatility index and valuation index.
AC Immune SA (ACIU) was downgraded to E+ from D- on 4/12/2024 due to a decline in the volatility index and valuation index.
D
Sell
8/24/2023Upgraded
AC Immune SA (ACIU) was upgraded to D- from E+ on 8/24/2023 due to an increase in the volatility index and total return index.
AC Immune SA (ACIU) was upgraded to D- from E+ on 8/24/2023 due to an increase in the volatility index and total return index.
E
Sell
8/9/2023Downgrade
AC Immune SA (ACIU) was downgraded to E+ from D- on 8/9/2023 due to a noticeable decline in the solvency index and volatility index. The quick ratio declined from 9.88 to 8.43.
AC Immune SA (ACIU) was downgraded to E+ from D- on 8/9/2023 due to a noticeable decline in the solvency index and volatility index. The quick ratio declined from 9.88 to 8.43.
D
Sell
8/4/2023Upgraded
AC Immune SA (ACIU) was upgraded to D- from E+ on 8/4/2023 due to an increase in the volatility index and total return index.
AC Immune SA (ACIU) was upgraded to D- from E+ on 8/4/2023 due to an increase in the volatility index and total return index.
E
Sell
7/19/2023Downgrade
AC Immune SA (ACIU) was downgraded to E+ from D- on 7/19/2023 due to a decline in the volatility index and valuation index.
AC Immune SA (ACIU) was downgraded to E+ from D- on 7/19/2023 due to a decline in the volatility index and valuation index.
D
Sell
6/29/2023Upgraded
AC Immune SA (ACIU) was upgraded to D- from E+ on 6/29/2023 due to an increase in the volatility index and total return index.
AC Immune SA (ACIU) was upgraded to D- from E+ on 6/29/2023 due to an increase in the volatility index and total return index.
E
Sell
6/12/2023Downgrade
AC Immune SA (ACIU) was downgraded to E+ from D- on 6/12/2023 due to a decline in the volatility index.
AC Immune SA (ACIU) was downgraded to E+ from D- on 6/12/2023 due to a decline in the volatility index.
D
Sell
5/23/2023Upgraded
AC Immune SA (ACIU) was upgraded to D- from E+ on 5/23/2023 due to an increase in the volatility index.
AC Immune SA (ACIU) was upgraded to D- from E+ on 5/23/2023 due to an increase in the volatility index.
E
Sell
5/5/2023Downgrade
AC Immune SA (ACIU) was downgraded to E+ from D- on 5/5/2023 due to a decline in the volatility index.
AC Immune SA (ACIU) was downgraded to E+ from D- on 5/5/2023 due to a decline in the volatility index.
D
Sell
4/19/2023Upgraded
AC Immune SA (ACIU) was upgraded to D- from E+ on 4/19/2023 due to an increase in the total return index and volatility index.
AC Immune SA (ACIU) was upgraded to D- from E+ on 4/19/2023 due to an increase in the total return index and volatility index.
E
Sell
3/14/2023Downgrade
AC Immune SA (ACIU) was downgraded to E+ from D on 03/14/2023.
AC Immune SA (ACIU) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
AC Immune SA (ACIU) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
AC Immune SA (ACIU) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
AC Immune SA (ACIU) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index and volatility index.
AC Immune SA (ACIU) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
5/4/2022Upgraded
AC Immune SA (ACIU) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and valuation index.
AC Immune SA (ACIU) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and valuation index.
E
Sell
5/1/2022Downgrade
AC Immune SA (ACIU) was downgraded to E+ from D on 05/01/2022.
AC Immune SA (ACIU) was downgraded to E+ from D on 05/01/2022.
D
Sell
4/29/2022Upgraded
AC Immune SA (ACIU) was upgraded to D from D- on 4/29/2022 due to an increase in the growth index and solvency index. The quick ratio increased from 9.97 to 14.63, EBIT increased 20.19% from -$25.53M to -$20.38M, and earnings per share increased from -$0.2819 to -$0.2489.
AC Immune SA (ACIU) was upgraded to D from D- on 4/29/2022 due to an increase in the growth index and solvency index. The quick ratio increased from 9.97 to 14.63, EBIT increased 20.19% from -$25.53M to -$20.38M, and earnings per share increased from -$0.2819 to -$0.2489.
D
Sell
3/15/2022Downgrade
AC Immune SA (ACIU) was downgraded to D- from D on 3/15/2022 due to a decline in the volatility index and total return index.
AC Immune SA (ACIU) was downgraded to D- from D on 3/15/2022 due to a decline in the volatility index and total return index.
D
Sell
2/17/2022Upgraded
AC Immune SA (ACIU) was upgraded to D from D- on 2/17/2022 due to an increase in the volatility index.
AC Immune SA (ACIU) was upgraded to D from D- on 2/17/2022 due to an increase in the volatility index.
D
Sell
2/2/2022Downgrade
AC Immune SA (ACIU) was downgraded to D- from D on 2/2/2022 due to a major decline in the total return index and volatility index.
AC Immune SA (ACIU) was downgraded to D- from D on 2/2/2022 due to a major decline in the total return index and volatility index.
D
Sell
11/10/2021Upgraded
AC Immune SA (ACIU) was upgraded to D from D- on 11/10/2021 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.2879 to -$0.2396, and operating cash flow increased 10.25% from -$17.59M to -$15.79M.
AC Immune SA (ACIU) was upgraded to D from D- on 11/10/2021 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.2879 to -$0.2396, and operating cash flow increased 10.25% from -$17.59M to -$15.79M.
D
Sell
11/8/2021Downgrade
AC Immune SA (ACIU) was downgraded to D- from D on 11/8/2021 due to a significant decline in the growth index, solvency index and efficiency index. The quick ratio declined from 19.52 to 16.89, net income declined 13.33% from -$18.47M to -$20.94M, and earnings per share declined from -$0.2555 to -$0.2879.
AC Immune SA (ACIU) was downgraded to D- from D on 11/8/2021 due to a significant decline in the growth index, solvency index and efficiency index. The quick ratio declined from 19.52 to 16.89, net income declined 13.33% from -$18.47M to -$20.94M, and earnings per share declined from -$0.2555 to -$0.2879.
D
Sell
5/6/2020Downgrade
AC Immune SA (ACIU) was downgraded to D from D+ on 5/6/2020 due to a significant decline in the valuation index, efficiency index and volatility index. Total capital declined 2.14% from $284.31M to $278.21M.
AC Immune SA (ACIU) was downgraded to D from D+ on 5/6/2020 due to a significant decline in the valuation index, efficiency index and volatility index. Total capital declined 2.14% from $284.31M to $278.21M.
D
Sell
4/6/2020Downgrade
AC Immune SA (ACIU) was downgraded to D+ from C on 4/6/2020 due to a major decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.2536 to -$0.2734, EBIT declined 204.28% from $18.24M to -$19.02M, and operating cash flow declined 174.59% from $17.26M to -$12.88M.
AC Immune SA (ACIU) was downgraded to D+ from C on 4/6/2020 due to a major decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.2536 to -$0.2734, EBIT declined 204.28% from $18.24M to -$19.02M, and operating cash flow declined 174.59% from $17.26M to -$12.88M.
C
Hold
3/18/2020Upgraded
AC Immune SA (ACIU) was upgraded to C from C- on 3/18/2020 due to a noticeable increase in the total return index, valuation index and volatility index.
AC Immune SA (ACIU) was upgraded to C from C- on 3/18/2020 due to a noticeable increase in the total return index, valuation index and volatility index.
C
Hold
11/25/2019Upgraded
AC Immune SA (ACIU) was upgraded to C- from D+ on 11/25/2019 due to an increase in the volatility index and total return index.
AC Immune SA (ACIU) was upgraded to C- from D+ on 11/25/2019 due to an increase in the volatility index and total return index.
D
Sell
11/15/2019Upgraded
AC Immune SA (ACIU) was upgraded to D+ from D on 11/15/2019 due to a substantial increase in the valuation index, growth index and efficiency index. Total revenue increased 2,149.2% from $1.51M to $33.9M, EBIT increased 223.78% from -$14.73M to $18.24M, and operating cash flow increased 215.12% from -$14.99M to $17.26M.
AC Immune SA (ACIU) was upgraded to D+ from D on 11/15/2019 due to a substantial increase in the valuation index, growth index and efficiency index. Total revenue increased 2,149.2% from $1.51M to $33.9M, EBIT increased 223.78% from -$14.73M to $18.24M, and operating cash flow increased 215.12% from -$14.99M to $17.26M.
D
Sell
8/15/2019Downgrade
AC Immune SA (ACIU) was downgraded to D from D+ on 8/15/2019 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 126.42% from $63.78M to -$16.85M, earnings per share declined from $0.9088 to -$0.2394, and EBIT declined 124.41% from $60.35M to -$14.73M.
AC Immune SA (ACIU) was downgraded to D from D+ on 8/15/2019 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 126.42% from $63.78M to -$16.85M, earnings per share declined from $0.9088 to -$0.2394, and EBIT declined 124.41% from $60.35M to -$14.73M.
D
Sell
5/31/2019Upgraded
AC Immune SA (ACIU) was upgraded to D+ from D on 5/31/2019 due to an increase in the total return index and volatility index.
AC Immune SA (ACIU) was upgraded to D+ from D on 5/31/2019 due to an increase in the total return index and volatility index.
D
Sell
5/24/2019Upgraded
AC Immune SA (ACIU) was upgraded to D from D- on 5/24/2019 due to a significant increase in the growth index, valuation index and efficiency index. Total revenue increased 5,242.68% from $1.41M to $75.29M, operating cash flow increased 660.65% from -$11.81M to $66.2M, and net income increased 532.67% from -$14.74M to $63.78M.
AC Immune SA (ACIU) was upgraded to D from D- on 5/24/2019 due to a significant increase in the growth index, valuation index and efficiency index. Total revenue increased 5,242.68% from $1.41M to $75.29M, operating cash flow increased 660.65% from -$11.81M to $66.2M, and net income increased 532.67% from -$14.74M to $63.78M.
D
Sell
3/29/2019Downgrade
AC Immune SA (ACIU) was downgraded to D- from D on 3/29/2019 due to a decline in the total return index, efficiency index and growth index. Total revenue declined 39.83% from $2.34M to $1.41M, EBIT declined 17.68% from -$12.37M to -$14.55M, and total capital declined 8.23% from $197.28M to $181.05M.
AC Immune SA (ACIU) was downgraded to D- from D on 3/29/2019 due to a decline in the total return index, efficiency index and growth index. Total revenue declined 39.83% from $2.34M to $1.41M, EBIT declined 17.68% from -$12.37M to -$14.55M, and total capital declined 8.23% from $197.28M to $181.05M.
D
Sell
7/17/2018Upgraded
AC Immune SA (ACIU) was upgraded to D from D- on 7/17/2018 due to an increase in the total return index and volatility index.
AC Immune SA (ACIU) was upgraded to D from D- on 7/17/2018 due to an increase in the total return index and volatility index.
D
Sell
7/2/2018Downgrade
AC Immune SA (ACIU) was downgraded to D- from D on 7/2/2018 due to a decline in the total return index and volatility index.
AC Immune SA (ACIU) was downgraded to D- from D on 7/2/2018 due to a decline in the total return index and volatility index.
D
Sell
5/24/2018Upgraded
AC Immune SA (ACIU) was upgraded to D from D- on 5/24/2018 due to an increase in the total return index and valuation index.
AC Immune SA (ACIU) was upgraded to D from D- on 5/24/2018 due to an increase in the total return index and valuation index.
D
Sell
5/7/2018Downgrade
AC Immune SA (ACIU) was downgraded to D- from D on 5/7/2018 due to a large decline in the efficiency index, growth index and solvency index. EBIT declined 469.7% from $3.23M to -$11.94M, net income declined 390.35% from $4.22M to -$12.25M, and earnings per share declined from $0.0737 to -$0.2136.
AC Immune SA (ACIU) was downgraded to D- from D on 5/7/2018 due to a large decline in the efficiency index, growth index and solvency index. EBIT declined 469.7% from $3.23M to -$11.94M, net income declined 390.35% from $4.22M to -$12.25M, and earnings per share declined from $0.0737 to -$0.2136.
D
Sell
10/2/2017Upgraded
AC Immune SA (ACIU) was upgraded to D from D- on 10/02/2017.
AC Immune SA (ACIU) was upgraded to D from D- on 10/02/2017.
D
Sell
6/1/2017Upgraded
AC Immune SA (ACIU) was upgraded to D- from E on 6/1/2017 due to a noticeable increase in the solvency index, growth index and valuation index. Total revenue increased 39.82% from $1.43M to $2M, the quick ratio increased from 15.48 to 18.3, and EBIT increased 13.84% from -$9.06M to -$7.81M.
AC Immune SA (ACIU) was upgraded to D- from E on 6/1/2017 due to a noticeable increase in the solvency index, growth index and valuation index. Total revenue increased 39.82% from $1.43M to $2M, the quick ratio increased from 15.48 to 18.3, and EBIT increased 13.84% from -$9.06M to -$7.81M.
E
Sell
3/1/2017Upgraded
AC Immune SA (ACIU) was upgraded to E from E- on 3/1/2017 due to an increase in the total return index and valuation index.
AC Immune SA (ACIU) was upgraded to E from E- on 3/1/2017 due to an increase in the total return index and valuation index.
E
Sell
12/16/2016None
AC Immune SA (ACIU) was downgraded to E- from U on 12/16/2016.
AC Immune SA (ACIU) was downgraded to E- from U on 12/16/2016.
NASDAQ
04/02/2025 4:00PM Eastern
Quotes delayed
